Hints and tips:
...Ryan Richardson, chief strategy officer at BioNTech, said the company was focused on the mid-to-long term and that most of the shareholders were long-term investors....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Ryan Richardson, chief strategy officer for BioNTech, told the FT Global Pharmaceutical and Biotechnology Conference on Tuesday that the company would adopt “differential pricing” in different regions and...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Ryan McMorrow 16....
...behind hit Fox shows such as The People v OJ Simpson and Glee....
...“Most of the defendants have a documented history of paying bribes that supported terrorism under Saddam,” said Ryan Sparacino, one of the plaintiffs’ attorneys....
...(NYT) News Round-up Private equity funds receive record amounts of capital (FT) China’s hobbled dealmakers yield foreign M&A crown to Japan Inc....
...Ryan himself....
...(WaPo) Clinton v Trump: clash of the operatives David Brock and Roger Stone are masters of the dark arts of politics – 2016 will be their greatest canvas....
...Ian Read, chief executive of New York-based Pfizer, said last week the US tax code left his team “with one hand tied behind our back” in competition with foreign rivals....
...The Obama administration had been waiting to see if Paul Ryan’s chairmanship of the House of Representatives’ tax committee this year would spur legislative reform, but turmoil in the Republican party and...
...Paul Ryan, speaker of the US House of Representatives, last month said: “Trillions of dollars of American capital are locked out of the United States and, as a result, US companies are being targeted by...
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Athersys shares more than doubled to $2.40 while Pfizer, the world’s largest drugmaker, was up 1.7 per cent to $18.61....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...“The case is important because it affects so many Americans and so much money,” said Ryan Leggio, an analyst at Morningstar....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...“The case for mergers in the pharmaceutical industry can be convincingly and unequivocally made at the current time,” say Deutsche Bank analysts Barbara Ryan and George Drivas in a recent report....
...Barbara Ryan, research analyst at Deutsche Bank, believes Pfizer, Merck and BMS are all well positioned to make transforming acquisitions....
...Barbara Ryan, analyst at Deutsche Bank, said: “Recent actions to significantly reduce corporate overhead, and increase long-term earnings visibility, are clearly a positive, but need to be followed by strategic...
International Edition